A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer

Palbociclib for HR positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (POLAR)

Study Co-Chairs
Elisabetta Munzone, MD, Milan, Italy
Prof. Stefan Aebi, MD, Lucerne, Switzerland


Statistician
Meredith Regan, Yue Ren

Trial Coordinator
Meredith Kissel

Data Manager
Adriana Karausch, Dorene Polizzi

IBCSG Data Management Center/Frontier Science Foundation
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email:

This email address is being protected from spambots. You need JavaScript enabled to view it.


Monitoring
ETOP IBCSG Partners Foundation
Coordinating Center, Bern, Switzerland
Phone: +41 31 511 94 00
Fax: +41 31 511 94 01
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


Date of Activation
June 25, 2019

Targeted Accrual
400

Protocol Release Date 
December 07, 2018

Trial Activation Date 
June 25, 2019

First Patient In 
August 27, 2019

Accrual Closure Date 
N/A

Global Trial Completion Date
N/A

ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org

Member Login